The act of reversing policies intended to decrease the cost of pharmaceuticals occurred during the Trump administration. Several initiatives aimed at achieving this goal were proposed and, in some cases, implemented, only to be subsequently withdrawn or significantly altered. These policies ranged from allowing the importation of drugs from Canada to requiring rebates from pharmaceutical manufacturers.
Lowering prescription drug costs remains a significant concern for many Americans, particularly those with chronic illnesses or limited incomes. Efforts to address high drug prices have historically faced strong opposition from pharmaceutical companies and lobbying groups who argue that reduced prices stifle innovation and research. The economic and political landscape surrounding drug pricing is complex, involving factors such as patent law, international trade agreements, and regulatory oversight.
